8-K: Assertio Holdings Acquired by Zydus for $23.50 Per Share

Assertio Holdings has completed its acquisition by Zydus Worldwide DMCC in an all-cash transaction valued at $23.50 per share.

Summary

• Assertio Holdings, Inc. has been acquired by Zydus Worldwide DMCC, a subsidiary of Zydus Lifesciences Ltd., for $23.50 per share in cash.
• The merger was consummated on June 16, 2026, following the expiration of the tender offer on June 15, 2026, where approximately 66.32% of outstanding shares were tendered.
• Assertio common stock has been delisted from the Nasdaq Stock Market.
• The merger triggered a Fundamental Change and Make-Whole Fundamental Change for the company's 6.50% Convertible Senior Notes due 2027.
• Holders of the Notes are entitled to convert each $1,000 principal amount into approximately $382.58 in cash or exercise a repurchase right at 100% of the principal amount plus accrued interest.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive outcome for shareholders who receive a definitive cash exit, though it marks the end of the company's independent public life.

Positives

• Stockholders received a definitive cash exit at $23.50 per share.
• The transaction provides immediate liquidity to shareholders.
• The merger was successfully completed with a clear path for noteholders to either convert or seek repurchase.

Negatives

• The company's common stock has been delisted from the Nasdaq.
• The conversion value for the 6.50% Convertible Senior Notes ($382.58 per $1,000 principal) is significantly below par value, reflecting the impact of the merger on the noteholders' potential upside.

Risks

• Noteholders face a potential loss of value if they choose to convert, as the cash consideration per $1,000 note is substantially lower than the principal amount.
• The company is now a wholly-owned subsidiary, eliminating public equity participation.

Future Outlook

Assertio will operate as a wholly-owned subsidiary of Zydus Lifesciences. The company has terminated its public reporting obligations and delisted its shares.

Management Comments

• The company announced the successful completion of the merger and provided notice of the Fundamental Change to noteholders.

Industry Context

StockSavvy.ai notes that this acquisition follows a trend of consolidation in the specialty pharmaceutical sector, where larger global players like Zydus are acquiring smaller, niche commercial-stage companies to bolster their oncology portfolios.

Comparison to Industry Standards

• The $23.50 cash-out price represents a standard premium-based exit for a mid-cap pharmaceutical company.
• The treatment of convertible notes in a change-of-control event aligns with standard indenture provisions for 'Make-Whole' fundamental changes.

Management Changes

Corporate Governance

Legal Proceedings

• None disclosed beyond standard merger-related regulatory filings.

Related Party Transactions

• None disclosed.

Stakeholder Impact

• Shareholders receive cash consideration.
• Noteholders face a decision regarding conversion or repurchase.
• Employees and management face transition to new ownership structure.

Next Steps

• Noteholders must decide whether to convert or tender for repurchase by July 16, 2026.
• Company to file Form 15 to terminate registration of shares under the Exchange Act.

Key Dates

Keywords

Merger, Acquisition, Assertio Holdings, Zydus Lifesciences, Convertible Notes, Tender Offer, Delisting